Molecular subtypes and optimal treatments for breast cancer are usually based on immunohistochemical markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The gene discussed is ERBB2; the disease is breast carcinoma.